What is the tissue of origin for breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Breast cancer originates from the epithelial tissue of the breast, specifically from the cells lining the milk ducts (ductal carcinoma) or the milk-producing lobules (lobular carcinoma), with approximately 85% to 90% of invasive carcinomas being ductal in origin. The malignant transformation occurs when these epithelial cells undergo genetic mutations that disrupt normal cell growth and division mechanisms, as noted in studies such as 1 and 1. These mutations can affect genes responsible for cell cycle regulation, DNA repair, and apoptosis (programmed cell death), leading to uncontrolled proliferation of abnormal cells. The transformed cells can remain within the ducts or lobules (in situ carcinoma) or invade surrounding breast tissue (invasive carcinoma).

Key points to consider include:

  • The spectrum of proliferative abnormalities in the breast, including hyperplasia, atypical hyperplasia, in situ carcinoma, and invasive carcinoma, as discussed in 1 and 1.
  • The importance of understanding the tissue of origin in guiding treatment approaches, as it explains why breast cancer typically begins in the ducts or lobules before potentially spreading to nearby tissues and lymph nodes.
  • Various factors that can influence the development of breast cancer, including genetic predisposition (such as BRCA1/BRCA2 mutations), hormonal factors, and environmental exposures, as mentioned in 1.

Given the information from the most recent and highest quality studies, such as 1, the tissue of origin for breast cancer is primarily the ductal epithelium, with a smaller proportion originating from the lobular epithelium. This understanding is crucial for developing effective treatment strategies and improving patient outcomes.

From the Research

Tissue of Origin for Breast Cancer

The tissue of origin for breast cancer is the epithelial cells lining the ducts or lobules of the breast 2.

Epithelial Cells and Breast Cancer

  • Epithelial cells can be divided into light and dark cells using electron density 3
  • The normal mammary gland can be roughly divided into the large duct close to the nipple and the terminal duct located within the lobulus, both composed of epithelial cells and myoepithelial cells 3
  • Breast cancer arises from epithelial cells lining the breast ducts and lobules 4

Terminal Ductal-Lobular Unit

  • The terminal ductal-lobular unit is the site of origin for most breast diseases, including hyperplasias and neoplasia 5
  • The terminal ductal-lobular unit is drained by a terminal duct attached to the main duct system 5

Ductal Carcinoma In Situ (DCIS)

  • DCIS represents a proliferation of malignant epithelial cells within the ducts and lobules of the breast, without invasion through the basement membrane 6
  • DCIS is heterogeneous with respect to its clinical presentation, mammographic abnormalities, histology, and biology 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Risk-reducing mastectomy.

Journal of long-term effects of medical implants, 2006

Research

Electron microscopic findings for diagnosis of breast lesions.

Medical molecular morphology, 2005

Research

On the origin and progression of human breast cancer.

American journal of obstetrics and gynecology, 1986

Research

Ductal carcinoma in situ of the breast: histological classification and genetic alterations.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.